Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies

Brain

Volumn 139, Issue 10, 2016, Pages 2740-2750

  Sarro, Lidia ^a,b   Senjem, Matthew L ^a   Lundt, Emily S ^a   Przybelski, Scott A ^a   Lesnick, Timothy G ^a   Graff Radford, Jonathan ^a   Boeve, Bradley F ^a   Lowe, Val J ^a   Ferman, Tanis J ^c   Knopman, David S ^a   Comi, Giancarlo ^b   Filippi, Massimo ^b   Petersen, Ronald C ^a   Jack, Clifford R ^a   Kantarci, Kejal ^a  

^a MAYO CLINIC   (United States)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c MAYO CLINIC   (United States)

Author keywords

amyloid imaging; beta amyloid; brain atrophy; DLB; structural MRI

Indexed keywords

AMYLOID BETA PROTEIN; LEVODOPA; PITTSBURGH COMPOUND B;

AGED; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL DEMENTIA RATING; COHORT ANALYSIS; DIFFUSE LEWY BODY DISEASE; FEMALE; FOLLOW UP; GRAY MATTER; HUMAN; MALE; MEDIAL TEMPORAL LOBE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; PUTAMEN; THREE DIMENSIONAL IMAGING; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; TRENDS;

AGED; AMYLOID BETA-PEPTIDES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAY MATTER; HUMANS; LEWY BODY DISEASE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY;

EID: 84991038998     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww193     Document Type: Article

References (83)

1. Andrews KA, Modat M, Macdonald KE, Yeatman T, Cardoso MJ, Leung KK, et al. Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials. PLoS One 2013; 8: e58816.
2. Araque Caballero MA, Brendel M, Delker A, Ren J, Rominger A, Bartenstein P, et al. Mapping 3-year changes in gray matter and metabolism in Abeta-positive nondemented subjects. Neurobiol Aging 2015; 36: 2913-24.
3. Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006; 60: 145-7.
4. Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeo-morphic image registration with cross-correlation: evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 2008; 12: 26-41.
5. Boeve BF, Molano JR, Ferman TJ, Smith GE, Lin SC, Bieniek K, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med 2011; 12: 445-53.
6. Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behav Brain Res 2011; 221: 564-73.
7. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
8. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010; 74: 77-84.
9. Burton EJ, Barber R, Mukaetova-Ladinska EB, Robson J, Perry RH, Jaros E, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 2009; 132 (Pt 1): 195-203.
10. Cash DM, Frost C, Iheme LO, Unay D, Kandemir M, Fripp J, et al. Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. Neuroimage 2015; 123: 149-64.
11. Catafau AM, Bullich S. Amyloid PET imaging: applications beyond Alzheimer's disease. Clin Transl Imaging 2015; 3: 39-55.
12. Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010; 67: 317-24.
13. Chetelat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, et al. Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology 2012; 78: 477-84.
14. Claassen DO, Lowe VJ, Peller PJ, Petersen RC, Josephs KA. Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy. Parkinsonism Relat Disord 2011; 17: 160-5.
15. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic Interactions between Abeta, tau, and alpha-synu-clein: acceleration of neuropathology and cognitive decline. J Neurosci 2010; 30: 7281-9.
16. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011; 134 (Pt 5): 1493-505.
17. De Beer M, Teunissen C, Van der Flier W, Sikkes S, Lemstra A. Dementia with Lewy bodies and Alzheimer's disease: an unfortunate couple. Am J Neurodegener Dis 2015; 4: 1-178.
18. Dore V, Villemagne VL, Bourgeat P, Fripp J, Acosta O, Chetelat G, et al. Cross-sectional and longitudinal analysis of the relationship between Abeta deposition, cortical thickness, and memory in cogni-tively unimpaired individuals and in Alzheimer disease. JAMA Neurol 2013; 70: 903-11.
19. Driscoll I, Troncoso JC, Rudow G, Sojkova J, Pletnikova O, Zhou Y, et al. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol 2012; 124: 823-31.
20. Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002a; 52: 205-10.
21. Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VM, et al. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol 2002b; 104: 7-11.
22. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008; 79: 1331-8.
23. Ferman TJ, Aoki N, Murray ME, Boeve BF, Graff-Radford N, Van Gerpen J, et al. disease trajectory and cognitive profiles of three pathologic subtypes of DLB. Am J Neurodegener Dis 2015; 4 (Suppl 1): 1-178.
24. Ferman TJ, Smith GE, Boeve BF, Ivnik RJ, Petersen RC, Knopman D, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004; 62: 181-7.
25. Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, et al. In vitro characterization of Pittsburgh com-pound-B binding to Lewy bodies. J Neurosci 2007; 27: 10365-71.
26. Foster ER, Campbell MC, Burack MA, Hartlein J, Flores HP, Cairns NJ, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010; 25: 2516-23.
27. Gomperts SN, Locascio JJ, Marquie M, Santarlasci AL, Rentz DM, Maye J, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012; 27: 965-73.
28. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71: 903-10.
29. Graff-Radford J, Lesnick T, Boeve BF, Przybelski S, Ferman TJ, Jones D, et al. Predicting Survival in Dementia with Lewy Bodies with Hippocampal Volumetry. Am J Neurodegener Dis 2015; 4 (Suppl 1): 1-178.
30. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, et al. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 2013; 154: 103-17.
31. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001; 102: 355-63.
32. Howlett DR, Whitfield D, Johnson M, Attems J, O'Brien JT, Aarsland D, et al. Regional multiple pathology scores are associated with cognitive decline in lewy body dementias. Brain Pathol 2015; 25: 401-8.
33. Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 2003; 62: 389-97.
34. Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131 (Pt 3): 665-80.
35. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132 (Pt 5): 1355-65.
36. Jack CR Jr, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004; 62: 591-600.
37. Jack CR Jr, Therneau TM, Wiste HJ, Weigand SD, Knopman DS, Lowe VJ, et al. Transition rates between amyloid and neurodegen-eration biomarker states and to dementia: a population-based, longitudinal cohort study. Lancet Neurol 2016; 15: 56-64.
38. Jack CR Jr, Wiste HJ, Knopman DS, Vemuri P, Mielke MM, Weigand SD, et al. Rates of beta-amyloid accumulation are independent of hippocampal neurodegeneration. Neurology 2014; 82: 1605-12.
39. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-16.
40. Jellinger KA, Attems J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol 2006; 112: 253-60.
41. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. Striatal beta-amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol 2008; 67: 155-61.
42. Kantarci K, Ferman TJ, Boeve BF, Weigand SD, Przybelski S, Vemuri P, et al. Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology 2012a; 79: 553-60.
43. Kantarci K, Lowe VJ, Boeve BF, Weigand SD, Senjem ML, Przybelski SA, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2012b; 33: 2091-105.
44. Kantarci K, Yang C, Schneider JA, Senjem ML, Reyes DA, Lowe VJ, et al. Antemortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging 2012c; 33: 878-85.
45. Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010; 74: 885-92.
46. Knopman DS, Jack CR Jr, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with beta-amyloidosis. JAMA Neurol 2013; 70: 1030-8.
47. Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, et al. Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia. Arch Neurol 2012; 69: 1326-31.
48. Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, et al. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation. Exp Neurol 2004; 187: 279-88.
49. Kraybill ML, Larson EB, Tsuang DW, Teri L, McCormick WC, Bowen JD, et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 2005; 64: 2069-73.
50. Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology 1993; 43: 1927-34.
51. Lowe VJ, Kemp BJ, Jack CR Jr, Senjem M, Weigand S, Shiung M, et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med 2009; 50: 878-86.
52. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009; 34: 107-12.
53. Mak E, Li S, Williams GB, Watson R, Firbank M, Blamire A, et al. Differential Atrophy of hippocampal subfields: a comparative study of dementia with lewy bodies and Alzheimer disease. Am J Geriatr Psychiatry 2016: 24: 136-43.
54. Mak E, Su L, Williams GB, Watson R, Firbank M, Blamire AM, et al. Longitudinal assessment of global and regional atrophy rates in Alzheimer's disease and dementia with Lewy bodies. Neuroimage Clin 2015a; 7: 456-62.
55. Mak E, Su L, Williams GB, Watson R, Firbank MJ, Blamire AM, et al. Progressive cortical thinning and subcortical atrophy in dementia with Lewy bodies and Alzheimer's disease. Neurobiol Aging 2015b; 36: 1743-50.
56. McCleery J, Morgan S, Bradley KM, Noel-Storr AH, Ansorge O, Hyde C. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. Cochrane Database Syst Rev 2015; 1: CD010633.
57. McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007; 6: 305-13.
58. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005; 65: 1863-72.
59. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001; 50: 358-65.
60. Murray ME, Ferman TJ, Boeve BF, Przybelski SA, Lesnick TG, Liesinger AM, et al. MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. Neurology 2013; 81: 1681-9.
61. Nedelska Z, Ferman TJ, Boeve BF, Przybelski SA, Lesnick TG, Murray ME, et al. Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol Aging 2015; 36: 452-61.
62. Nelson PT, Kryscio RJ, Jicha GA, Abner EL, Schmitt FA, Xu LO, et al. Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology 2009; 73: 1127-33.
63. O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004; 61: 919-25.
64. Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 2013; 74: 199-208.
65. Petersen RC, Wiste HJ, Weigand SD, Rocca WA, Roberts RO, Mielke MM, et al. Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community. JAMA Neurol 2016; 73: 85-92.
66. Petrou M, Dwamena BA, Foerster BR, MacEachern MP, Bohnen NI, Muller ML, et al. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord 2015; 30: 928-35.
67. Sabattoli F, Boccardi M, Galluzzi S, Treves A, Thompson PM, Frisoni GB. Hippocampal shape differences in dementia with Lewy bodies. Neuroimage 2008; 41: 699-705.
68. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197-204.
69. Shimada H, Shinotoh H, Hirano S, Miyoshi M, Sato K, Tanaka N, et al. beta-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. Mov Disord 2013; 28: 169-75.
70. Teune LK, Bartels AL, de Jong BM, Willemsen AT, Eshuis SA, de Vries JJ, et al. Typical cerebral metabolic patterns in neurodegen-erative brain diseases. Mov Disord 2010; 25: 2395-404.
71. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-53.
72. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-89.
73. Vemuri P, Whitwell JL, Kantarci K, Josephs KA, Parisi JE, Shiung MS, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem braak neurofibrillary tangle stage. Neuroimage 2008; 42: 559-67.
74. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013; 12: 357-67.
75. Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011; 52: 1210-17.
76. Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 2004; 62: 1568-72.
77. Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002; 73: 134-40.
78. Whitwell JL, Jack CR Jr, Parisi JE, Knopman DS, Boeve BF, Petersen RC, et al. Rates of cerebral atrophy differ in different degenerative pathologies. Brain 2007a; 130 (Pt 4): 1148-58.
79. Whitwell JL, Tosakulwong N, Weigand SD, Senjem ML, Lowe VJ, Gunter JL, et al. Does amyloid deposition produce a specific atro-phic signature in cognitively normal subjects? Neuroimage Clin 2013; 2: 249-57.
80. Whitwell JL, Weigand SD, Shiung MM, Boeve BF, Ferman TJ, Smith GE, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 2007b; 130 (Pt 3): 708-19.
81. Wolozin B, Behl C. Mechanisms of neurodegenerative disorders: part 1: protein aggregates. Arch Neurol 2000; 57: 793-6.
82. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005; 34: 561-6.
83. Zhong J, Pan P, Dai Z, Shi H. Voxelwise meta-analysis of gray matter abnormalities in dementia with Lewy bodies. Eur J Radiol 2014; 83: 1870-4.